Clinical trial
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary…
NCT00112671 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00112671 |
|---|---|
| Title | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract |
| Official title | A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 17 |
| Start date | Apr 1, 2005 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jun 3, 2005 |
| Last update posted | Jul 27, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: